

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIQUIDIA TECHNOLOGIES, INC.
Petitioner

v.

UNITED THERAPEUTICS CORPORATION
Patent Owner

Patent No. 10,716,793 B2
Issue Date: July 21, 2020
Title: TREPROSTINIL ADMINISTRATION BY INHALATION

Inter Partes Review No. IPR2021-00406

DECLARATION OF DR. FRIEDRICH GRIMMINGER

4833-1103-2795

I, Dr. Friedrich Grimminger, hereby declare as follows:

1. I am a member of University of Giessen and Marburg Lung Center (“UGMLC”), a research center at the University Hospital Giessen studying pulmonary hypertension.

2. I am not a paid consultant for United Therapeutics Corporation, which I understand is the assignee of U.S. Patent No. 10,716,793.

Ghofrani Review Article

3. I am a co-author of the German language article: Hossein Ardeschir Ghofrani *et al.* “Neue Therapieoptionen in der Behandlung der pulmonalerteriellen Hypertonie,”¹ *Herz*, 30, 4 (June 2005): 296-302 (“the Ghofrani article”). I understand that Liquidia Technologies, Inc. (“Liquidia”) submitted this publication along with an English language translation of the article in this proceeding as Exhibit 1010, which I have reviewed.

4. Dr. Frank Reichenberger and I both have experience in the use of selective endothelin A receptor agonists for treatment pulmonary hypertension. Therefore, we were asked by Dr. Werner Seeger to draft and, indeed, drafted the section of the Ghofrani article relating to selective endothelin A receptor agonists.

¹ The title is translated as “Pulmonary hypertension – new aspects of therapy” in Exhibit 1010.

In Exhibit 1010, this section is in English on page 11. In line with the normal practice in the UGMLC research center, both Dr. Reichenberger and I were listed as authors on the Ghofrani article for this contribution.

5. I did not make material contributions to any other section of the Ghofrani article, and I specifically did not contribute to the following excerpt:

Initial trials in Giessen have shown proof of efficacy of inhaled treprostinil for the effective reduction of the pulmonary vascular resistance (PVR) [6]. In this first study, 17 patients with severe pre-capillary pulmonary hypertension were administered inhaled treprostinil (15 mcg/inhalation). This led to a major reduction in pulmonary selective pressure and resistance with an overall duration of action of > 180 min. In direct comparison with inhaled iloprost, inhaled treprostinil showed a stronger pulmonary selectivity, so that it is possible to increase the dosage to up to 90 mcg (absolute inhaled dose per inhalation exercise) without adverse effects occurring [6]. Due to these unique properties (pronounced pulmonary selectivity and long duration of action after an individual inhalation), it is possible to reduce the number inhalations necessary to up to four per day; the inhalation period can be reduced to < 1 min. by selecting a suitable device. Additionally, the initial data shows that it is technically feasible for there to be only one to two breaths in an application.

(Ex. 1010, p. 11). The information in this excerpt was compiled and composed by Dr. Robert Voswinckel and Dr. Werner Seeger, and the idea to perform the underlying work originated with at least them.

6. Dr. Hossein A. Ghofrani—the first listed author—drafted the section of the Ghofrani article relating to phosphodiesterase inhibitors, and the remaining sections on vasoactive therapy, inhaled iloprost, combination therapies, and treatment of early forms of treatment of pulmonary hypertension, as well as the introduction were drafted by Dr. Hossein A. Ghofrani and Dr. Werner Seeger.

Voswinckel 2006 Clinical Observation Letter

7. I am listed as a co-author of the clinical observation letter: Robert Voswinckel, Hossein A. Ghofrani, Friedrich Grimminger, Werner Seeger, and Horst Olschewski, “Clinical Observations” on “Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension,” “Letters” Section of the Annals of Internal Medicine, 144(2):149-50 (January 2006) (“Voswinckel 2006”). I understand that Liquidia submitted the letter in this proceeding as Exhibit 1009, which I have reviewed.

8. I am listed as a co-author on the Voswinckel 2006 clinical observation letter because it was and is the practice of our group to include as authors of abstracts and summary review articles the members of our group who contribute to or oversee any part in the trials, clinical routine management, or related parallel studies, not just members who were directly responsible for conceiving, analyzing, and designing a particular study. This is typical of our group and a valid publication practice.

9. This same publication practice is reflected in other abstracts, such as: Voswinckel, R., *et al.*, Abstract 218: “Inhaled treprostinil is a potent pulmonary vasodilator in severe pulmonary hypertension,” *European Heart Journal* 25:22 (2004) (“Voswinckel JESC”) and Robert Voswinckel, *et al.*, Abstract 1414: “Inhaled Treprostinil Sodium (TRE) For the Treatment of Pulmonary Hypertension,” Abstracts from the 2004 Scientific Sessions of the American Heart Association, *Circulation*, 110(17 Suppl.):III-295 (October 26, 2004) (“Voswinckel JAHA”), which I understand Liquidia submitted in this proceeding as Exhibit 1007 and Exhibit 1008, respectively.

10. In each of Voswinckel JESC and Voswinckel JAHA, I am listed as a co-author on that abstract because it was and is the practice of our group to include as authors of abstracts and summary review articles the members of our group who contribute to or oversee any part in the trials, clinical routine management, or related parallel studies, not just members who were directly responsible for conceiving, analyzing, and designing a particular study.

11. In the case of any studies of inhaled treprostinil described in these documents (Voswinckel 2006, Voswinckel JESC and Voswinckel JAHA), I was listed as a co-author because I assisted with the clinical responsibilities of overseeing patients and was performing work related to the treatment of pulmonary

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.